Stock AnalizU S Physical Therapy Inc. USPH
Medical/Nursing Services · IPO 1992 · data as of November 13, 2026
U S Physical Therapy Inc. (USPH) is a healthcare company listed in the US with a market value of about $1.5B. In the twelve months to September 30, 2026 it had revenue of $838M and net income of $30M, a net margin of 3.6%.
Its overall Stock Analiz score is 2.4 out of 5 (weak). The strongest part is shareholder returns (4/5); the weakest is value (0/5).
Key numbers: a price to free cash flow of 21.5, 5-year revenue growth of 13% a year, a 5-year average ROIC of 7%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 23% below the current price.
Score: 2.4 / 5
Checks passed
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
- 5-year revenue growth above 8% a year
- Profitable 5 years in a row
- Positive free cash flow
- Interest covered more than 5 times
- Liabilities below 60% of assets
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- 3-year free cash flow growth above 10% a year
- Strong R&D investment or growth above 20%
- 5-year EPS growth above 10% a year
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $838M | $781M | $671M | $605M | $553M | $495M | $423M | $482M | $454M | $414M | $357M |
| Net income | $30M | $40M | $31M | $28M | $32M | $41M | $35M | $40M | $35M | $22M | $21M |
| Free cash flow | $69M | $61M | $66M | $73M | $50M | $68M | $92M | $52M | $66M | $49M | $43M |
| EPS (diluted) | $-1.34 | $1.42 | $1.84 | $1.28 | $2.25 | $2.41 | $2.48 | $2.45 | $1.31 | $1.76 | $1.64 |
| Net margin | 3.6% | 5.1% | 4.7% | 4.7% | 5.8% | 8.2% | 8.3% | 8.3% | 7.7% | 5.4% | 5.8% |
| ROIC | — | 8.2% | 6.1% | 5.2% | 7.3% | 10.8% | 10.8% | 14.4% | 19.1% | 16.9% | 14.2% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 6 analysts is $111.50, 12% above the current price; targets range from $95.00 to $122.00; the consensus rating is “Buy”; expected EPS is $2.88 for the fiscal year ending December 31, 2026.
Frequently asked questions
Is U S Physical Therapy stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 23% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does U S Physical Therapy pay a dividend?
Yes. The dividend yield is about 1.85%, and it has paid dividends for 10 years in our data.
Is U S Physical Therapy a good stock to buy?
We do not give buy or sell advice. U S Physical Therapy scores 2.4 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.